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Purpose: To elucidate the incidence of cytochrome P450 1B1 (CYP1B1) and myocillin (MYOC) mutations in Korean
patients with primary congenital glaucoma (PCG).
Methods: Genomic DNA was collected from peripheral blood of 85 unrelated Korean patients who were diagnosed as
having PCG by standard ophthalmological examinations and screened for mutations in the CYP1B1 and MYOC genes by
using bi-directional sequencing.
Results: Among 85 patients with PCG, 22 patients (22/85; 25.9%) had either one (n=11) or two (n=11) mutant alleles of
the  CYP1B1  gene.  Among  11  different  CYP1B1  mutations  identified,  a  frameshift  mutation  (c.970_971dupAT;
p.T325SfsX104) was the most frequent mutant allele (6/33; 18.2%) while p.G329S and p.V419Gfs11X were novel. In
the MYOC gene, two variants of unknown significance (p.L228S and p.E240G) were identified in two PCG patients (2/85;
2.4%), respectively. No patient had mutations in both genes.
Conclusions: Although CYP1B1 mutations are major causes of PCG in Korea, ~70% of PCG patients have neither
CYP1B1 nor MYOC mutations suggesting a high degree of genetic heterogeneity. Furthermore, the fact that 11 out of 22
patients had only one mutant allele in the CYP1B1 gene necessitates further investigation for other genetic backgrounds
underlying PCG.
Primary congenital glaucoma (PCG; OMIM 231300) is
a rare but severe form of glaucoma, which usually manifests
within the first year of life [1]. It is characterized by high
ocular  pressure  (IOP)  resulting  from  an  obstruction  of
aqueous outflow from the anterior segment of the eye, and is
thought to be the result of an anatomic defect in the trabecular
meshwork and anterior chamber [2]. Increased IOP causes
irreversible  damage  to  the  optic  nerve  and  can  lead  to
blindness  if  untreated.  Affected  children  typically  present
with  photophobia,  epiphora,  corneal  clouding,  and
enlargement of globe or cornea. PCG occurs in both familial
and  sporadic  patterns  [3].  Inheritance  in  familial  cases  is
usually  autosomal  recessive.  Incidence  of  PCG  is
geographically  and  ethnically  variable,  with  the  lowest
incidence (1:10,000) in the Western population and higher
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incidence  in  inbred  populations,  such  as  the  Gypsy
subpopulation of Slovakia (1:1,250) [4]. Three loci have been
mapped  for  PCG  (gene  symbol  GLC3),  GLC3A  (2p21;
OMIM  231300),  GLC3B  (1p36.2;  OMIM  600975),  and
GLC3C  (14q24.3).  The  gene  associated  with  GLC3A,
cytochrome  P450,  family  1,  subfamily  B,  polypeptide  1
(CYP1B1;  OMIM  601771),  has  been  implicated  in  the
pathogenesis of PCG. Physiologic studies have confirmed that
mutations  in  CYP1B1  can  cause  disease;  however,  the
pathway  by  which  CYP1B1  affects  development  of  the
anterior chamber of the eye is unknown. The proportion of
PCG patients whose disease is due to CYP1B1 mutations is
generally high, but varies among populations, ranging from
100%  in  Slovakian  Roma  to  ~10%  in  Mexico  [4,5].  No
responsible gene has yet been identified at the GLC3B and
GLC3C loci [6].
Of particular interest, the myocilin gene (MYOC; OMIM
601652), the first open angle glaucoma gene, was initially
reported  to  interact  with  CYP1B1  through  a  digenic
mechanism, leading to juvenile open angle glaucoma [7].
However,  MYOC  has  recently  been  implicated  in  the
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2093pathogenesis of some cases of PCG, either independently or
in association with CYP1B1 [8,9].
Herein, we screened both the CYP1B1 and MYOC genes
in 1 familial and 84 sporadic cases of PCG to identify the
underlying genetic mutations in a Korean population.
METHODS
Subjects: The study protocol adhered to the tenets of the
Declaration of Helsinki and informed consent was obtained
from patients or their responsible guardians. We conducted a
prospective  multi-institutional  collaborative  study  from
September, 2008 to February, 2010. A total of 85 unrelated
PCG patients were recruited from seven hospitals in South
Korea. Of the 85 cases, only one case was familial and the rest
were  sporadic.  Criteria  for  PCG  diagnosis  included  IOP
≥21 mmHg in at least one eye; megalocornea; corneal edema/
clouding/ opacity; and glaucomatous optic nerve head damage
when  examination  was  possible.  Corroborating  features
included symptoms of epiphora and photophobia. Patients
with other ocular or systemic anomalies were excluded.
To determine whether sequence variants identified were
polymorphic in Korean population, we used a panel of DNA
from 105 to 200 unrelated Korean individuals who attended
the clinic for conditions other than glaucoma.
Genetic  analyses  of  CYP1B1  and  MYOC  genes:  Blood
samples were taken from affected subjects and their parents
or relatives when possible. According to the manufacturer’s
instructions,  genomic  DNA  was  isolated  from  peripheral
blood leukocytes using the Wizard genomic DNA purification
kit (Promega, Madison, WI). Using the primers designed by
the authors (Table 1 and Table 2), entire coding exons and
flanking  intronic  sequences  of  CYP1B1  and  MYOC  were
amplified by polymerase chain reaction (PCR). Using the
BigDye Terminator Cycle Sequencing Ready Reaction kit
(Applied Biosystems, Foster City, CA), cycle sequencing of
CYP1B1 and MYOC was performed on the ABI 3100 Genetic
Analyzer (Applied Biosystems).
The Sequencher program (Gene Codes Corp., Ann Arbor,
MI)  was  used  for  analysis  of  sequence  variations  with
reference to the wild type sequence. Variations were described
according to guidelines established by the Human Genome
Variation Society (HGVS); the ‘A’ of the ATG codon for
translation initiation was numbered +1 and the 1st methionine
TABLE 1. PCR AND SEQUENCING PRIMERS FOR CYP1B1 GENE ANALYSIS.
Primer name Primer sequence (5'→3') Size (bp)
CYP1B1 1F TCTCCAGAGAGTCAGCTCCG 786
CYP1B1 1R GGGTCGTCGTGGCTGTAG
CYP1B1 2F ATGGCTTTCGGCCACTACT 787
CYP1B1 2R GATCTTGGTTTTGAGGGGTG
CYP1B1 3F AGTGAGAAATTAGGAAGCTGTTTTAGA 594
CYP1B1 3R GCCAGGATGGAGATGAAGAG
CYP1B1 4F CCCAAGGACACTGTGGTTTT 498
CYP1B1 4R AACGCTAATTGAGAAGCAGCA
                Annealing temperature, 60 °C for all primer pairs.
TABLE 2. PCR AND SEQUENCING PRIMERS FOR MYOC GENE ANALYSIS.
Primer name Primer sequence (5'→3') Size (bp)
MYOC 1F CTCTGTCTTCCCCCATGAAG 462
MYOC 1R AGCCTGGTCCAAGGTCAAT
MYOC 2F AGGCCATGTCAGTCATCCAT 478
MYOC 2R GCGCCTGTAGCAGGTCACTA
MYOC 3F GCAGCCTATTTAAATGTCATCCT 310
MYOC 3R TGGGTGGGCATTTACCCTAT
MYOC 4F TCCGCATGATCATTGTCTGT 467
MYOC 4R ACCCCAAGAATACGGGAACT
MYOC 5F ACTCGGGGAGCCTCTATTTC 461
MYOC 5R CTCCAGGGGGTTGTAGTCAA
MYOC 6F CCCAGAGAATCTGGAACTCG 478
MYOC 6R CGCCCTCAGACTACAATTCC
               Annealing temperature, 60 °C for all primer pairs.
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2094was  numbered  +1  (CYP1B1;  NP_000095.2,  MYOC;
NP_000252.1).  We  referred  to  the  CYP1B1  and  MYOC
mutation  database,  as  well  as  the  literature,  to  determine
whether a detected variation was novel or known [10]. When
a  novel  sequence  variant  was  identified,  400  ethnically
matched normal control chromosomes were tested for the
presence of the variant.
To assess the extent of conservation of a novel variation
in CYP1B1 thought to be associated with disease, the deduced
amino acid sequence was assessed by aligning the protein
sequences  of  different  mammalian  species  and  of  related
CYP1B1  family  members  using  ClustalW2  software
(European Bioinformatics Institute, Hinxton, UK).
RESULTS
Mutational analysis of CYP1B1: Eleven different mutations
in 22 sporadic cases were identified by direct sequencing of
the CYP1B1 gene in 85 PCG probands (Table 3). In total, three
subjects were homozygous for a CYP1B1 mutation and 8
Figure 1. Conservation of p.Gly329 residues (numeration according
to  human  CYP1B1,  as  shown  by  protein  alignment  of  several
CYP1B1  orthologs  and  other  CYP  family  members,  using
ClustalW2.
patients were compound heterozygous. Another 11 patients
were  heterozygous  for  a  CYP1B1  mutation.  Among  11
different  mutations,  two  novel  variations,  including  a
missense  variation  and  a  2-bp  deletion  (p.G329S  and
p.V419Gfs11X),  were  identified.  The  p.G329S  variation
occurs  in  a  highly  conserved  residue  (Figure  1)  and
p.V419Gfs11X causes a frameshift, resulting in a premature
termination  codon  at  residue  429  (Figure  2).  These  two
variations were not found in 400 normal chromosomes. The
remaining 9 mutations identified in our cohort have been
reported previously. They included the following missense
changes:  c.985G>T  (p.V320L),  c.988_989delinsTT
(p.A330F), c.1090G>A (p.V364M), c.1103G>A (p.R368H),
c.1169G>A (p.R390H), and c.1331G>A (p.R444Q), along
with  three  deleterious  mutations,  including  c.  55C>T
(p.Q19X),  c.243C>G  (p.T81X),  and  a  two  base  pair
duplication in exon 2 (c.970_971dupAT; p.T325SfsX104).
p.T325SfsX104 was the most frequent allele (18.2%, 6/33)
and  exhibited  compound  heterozygosity  with  p.T81X,
p.G329S, p.R390H, and p.R444Q, along with one case of
homozygosity (Table 3).
Eleven probands had only one identifiable mutant allele.
The mutations found in the heterozygous state were p.V320L,
p. A330F, p.V364M, and p.G329S.
In  addition  to  11  different  mutations,  7  previously
reported polymorphisms, c.-13C>T, c.142C>G (p.R48G), c.
319C>G  (p.L107V),  c.355G>T  (p.A119S),  c.729G>C
(p.V243V),  c.1294G>C  (p.V432L),  and  c.1347T>C  (p.
D449D) were detected (Table 4).
Mutational  analysis  of  MYOC:  Due  to  DNA  availability,
direct sequencing of MYOC was performed for 79 out of 85
patients. As a result, 2 patients were shown to harbor possible
novel  mutations  in  MYOC:  c.683T>C  (p.L228S)  and  c.
719A>G  (p.E240G),  respectively.  Neither  of  the  two
variations  was  found  in  400  normal  chromosomes.  Five
previously  described  polymorphisms,  including  c.34G>C
(p.G12R),  c.227G>A  (p.R76K),  c.624C>G  (p.D208E),  c.
730+35G>A,  and  c.1058C>T  (p.T353I)  were  identified
(Table 5). In addition, two novel synonymous variations, c.
864C>T  (p.I288I)  and  c.1110G>A  (p.P370P),  were  each
found  once  in  heterozigosity  (0.6%,  1/158).  These  two
variations were not found in 400 normal chromosomes.
DISCUSSION
Herein, we report on mutation screening of the CYP1B and
MYOC  genes  in  85  and  79  PCG  cases,  respectively.
CYP1B1 screening revealed that about 26% of 85 patients had
at least one mutation, although half of them carried only one
mutant  allele  with  the  other  mutation  unidentified.
Homozygisity of the mutant allele was seen in only three cases
and compound heterozygosity in eight cases. Consistent with
other CYP1B1 mutation spectrum studies from populations
where  consanguinity  is  uncommon,  we  observed  a  high
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degree of allelic heterogeneity and compound heterozygosity.
To  the  best  of  our  knowledge,  of  11  different  CYP1B1
mutations identified in the 85 probands, two are novel.
p.G329S has been previously reported as a pathologic
mutation for hepatocellular carcinoma [11]; however, in this
study, it was reported as a new causative mutation for PCG in
a  case  of  compound  heterozygosity  with  p.T325SfsX104
along with one each case of homozygosity and heterozygosity.
p.G329S  occurs  at  an  amino  acid  position  that  is  highly
conserved among other species and CYP1B1 family members
(Figure 1).
TABLE 3. CYP1B1 MUTATIONS IDENTIDIED IN KOREAN PROBANDS WITH PCG.
Patients Nucleotide change Amino acid change Hetero-/homozygous
PCG 11 c.[243C>G]+[1090G>A] p.[Y81X]+[V364M] Compound
heterozygous
PCG 17 c.[1090G>A]+[1090G>A] p.[V364M]+[V364M] Homozygous
PCG 18 c.[958G>T]+? p.[V320L]+[?] Heterozygous
PCG 20 c.[1090G>A]+? p.[V364M]+[?] Heterozygous
PCG 37 c.[958G>T]+? p.[V320L]+[?] Heterozygous
PCG 40 c.[970_971dupAT]+[985G>A] p.[T325SfsX104]+[G329S] Compound
heterozygous
PCG 45 c.[55C>T]+[1103G>A] p.[Q19X]+[R368H] Compound
heterozygous
PCG 46 c.1090G>A+? p.[V364M]+[?] Heterozygous
PCG 49 c.[243C>G]+[970_971dupAT] p.[Y81X]+[T325Sfs104X] Compound
heterozygous
PCG 53 c.[958G>T]+? p.[V320L]+[?] Heterozygous
PCG 54 c.[988_989delGCinsTT]+[1256_1257delTG] p.[A330F]+[V419GfsX11] Compound
heterozygous
PCG 55 c.[958G>T]+? p.[V320L]+[?] Heterozygous
PCG 6 c.[970_971dupAT]+[970_971dupAT] p.[T325SfsX104]+[T325SfsX104] Homozygous
PCG 69 c.[988_989delGCinsTT]+[1331G>A] p.[A330F]+[R444Q] Compound
heterozygous
PCG 72 c.[988_989delGCinsTT]+? p.[A330F]+[?] Heterozygous
PCG 73 c.[958G>T]+? p.[V320L]+[?] Heterozygous
PCG 74 c.[988_989delGCinsTT]+? p.[A330F]+[?] Heterozygous
PCG 75 c.[970_971dupAT]+[1331G>A] p.[T325SfsX104]+[R444Q] Compound
heterozygous
PCG 78 c.[970_971dupAT]+[1169G>A] p.[T325SfsX104]+[R390H] Compound
heterozygous
PCG 84 c.[988_989delGCinsTT]+? p.[A330F]+[?] Heterozygous
PCG 86 c.[985G>A]+[985G>A] p.[G329S]+[G329S] Homozygous
PCG 100 c.[985G>A]+[?] p.[G329S]+[?] Heterozygous
         *Reported as a causative mutation for hepatocellular adenoma. Bold lettering is used to represent novel mutations identified in
         this study.
Figure 2. Direct sequencing of the CYP1B1 gene. p.V419GfsX11 is a novel deletion mutation detected in a patient in the compound
heterozygous state.Among all of the mutations, p.T325SfsX104 was most
frequently found (6/33 mutant alleles). It is interesting to note
that this disease-causing mutation has only been described in
a single Japanese patient with PCG [12]. We speculated that
p.T325SfsX104 might be recurrent among Korean individuals
with PCG, possibly with a founder effect.
Although  the  presence  of  heterozygous  CYP1B1
mutations  in  11  PCG  patients  does  not  match  a  typical
recessive  pattern  of  inheritance  in  PCG,  heterozygous
CYP1B1 mutations have been documented [13-17]. Mutations
such as p.T81N, p.Q229K, p.R368H, and p.R469W have been
described  in  PCG  patients  in  the  heterozygous  state  [13,
15-18]. The mutations found in the heterozygous state in this
study were p.V320L, p.A330F, p.V364M, and p.G329S. As
described  above,  p.G329S  is  a  novel  mutation.  Since
p.V320L, p.A330F, and V364M, have not been reported in
heterozygous  state  [12,19-22],  additionally,  we  performed
population screening involving 210 control chromosomes. As
a result, p.A330F and p.V364M were not found in any normal
chromosome  and  p.V320L  was  occurred  in  less  than  1%
(2/210). As only the coding region of CYP1B1 was sequenced,
we  thought  that  it  might  be  due  to  mutations  in  (1)  the
CYP1B1 promoter or other non-coding regions; (2) genes
linked to other PCG loci, such as GLC3B and GLC3C; (3)
other glaucoma genes such as MYOC, resulting in digenic
inheritance;  or  (4)  some  other  unknown  genes  causing
glaucoma.  The  presence  of  double  heterozygous  variants,
CYP1B1 and MYOC, has recently been described in one PCG
case;  however,  the  role  of  possible  digenism  in  disease
causation  is  yet  to  be  established  [8,23].  PCG-causing
mutations in latent transforming growth factor beta binding
protein  2  (LTBP2;  OMIM  602091)  have  recently  been
identified in Pakistani, European Gypsy, and Iranian patients
[24,25]. LTBP2 lies very close to GLC3C on chromosome 14,
but is not strictly within the locus, as originally defined [26].
As such, it is not clear whether LTBP2 is the PCG-associated
gene within GLC3C, or whether the gene within this locus
remains unknown and LTBP2 defines a fourth locus for PCG.
Observation  of  unrelated  PCG  cases  with  a  heterozygous
mutation also raises the possibility that the mutation might be
a dominant cause of PCG [16].
Due to ethnic differences and geographical variations, the
prevalence of CYP1B1 mutations varies in different patient
populations, from ~10% in Mexico [5], to 20% in Indonesia
[27], Australia [28], China [29], and Japan [19]; around 40%
in Turkish patients [13]; approximately 50% in Brazil [20] and
France  [16];  and  about  100%  in  consanguineous  Saudi
Arabian [30] and Slovakian Gypsy [4] patients. Although
direct comparison between these studies is difficult, it should
be noted that the proportion of CYP1B1 mutations accounting
for PCG in our population is similar to those in Japan and
China.  These  data  also  illustrate  that  the  contribution  of
defects  in  this  gene  varies  significantly  among  human
populations, which highlights the need for analysis of large
groups of PCG from different ethnic backgrounds to ascertain
the role of this gene in a specific population.
Direct sequencing of the coding region of MYOC was
performed in 79 of all PCG probands. As a result, two variants
of  unknown  significance  (p.L228S  and  p.E240G)  were
identified in two PCG patients (2/79; 2.5%). These variations
lead  to  replacement  of  leucine  by  serine  at  codon  228
(p.L228S)  and  glutamic  acid  by  glycine  at  codon  240
(p.E240G), respectively, which involve a highly conserved
region among other species (Figure 3). Neither p.L228S nor
p.E240G was found in 400 control chromosomes, suggesting
that  these  two  variations  are  possible  mutations.  In  one
previous study, MYOC mutations accounted for 2.6% (3/116)
of Chinese patients with PCG [29].
Of the polymorphisms identified, p.G12R and p.T353I
have been previously reported as possible POAG causing
mutations; however, they were found in control subjects in
this study (Table 5). p.G12R, which has been reported as a
possible  disease-causing  mutation  in  a  sporadic  northern
Chinese case of POAG [31], was found in control subjects in
a few studies [32,33]. p.T353I was found in a Korean family
with  POAG  [34],  a  Japanese  patient  with  POAG  [35],
seventeen Chinese individuals with POAG [31-33,36], and
one Indian patient with juvenile-onset POAG [37]. However,
this  change  has  been  also  detected  in  normal  individuals
[33,36,38].  Therefore,  p.G12R  and  p.T353I  are  rare
polymorphisms  rather  than  disease-causing  mutations;
however, it remains possible that they affect the risk of POAG.
Reference SNP number
rs2617266
rs10012
rs56339482
rs1056827
rs9341249
rs1056836
rs1056537
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Location Nucleotide change Amino acid
change
Allele frequency (%)
Intron 1 5′UTR-13C>T NA C 130/170 (76.5) T 40/170 (23.5)
Exon 2 c.142C>G p.R48G C 130/170 (76.5) G 40/170 (23.5)
Exon 2 c.319C>G p.L107V C 166/170 (97.6) G 4/170 (2.4)
Exon 2 c.355G>T p.A119S G 129/170 (75.9) T 41/170 (24.1)
Exon 2 c.729G>C p.V243V G 165/170 (97.1) C 5/170 (2.9)
Exon 3 c.1294G>C p.V432L G 23/170 (13.5) C 147/170 (86.5)
Exon 3 c.1347T>C p.D449D T 27/170 (15.9) C 143/170 (84.1)
                Abbreviations: SNP, single nucleotide polymorphism; UTR, untranslated region; NA, not applicable.
TABLE 4. SINGLE NUCLEOTIDE POLYMORPHISMS OF CYP1B1 IDENTIFIED IN KOREAN PROBANDS WITH PCG.Molecular Vision 2011; 17:2093-2101 <http://www.molvis.org/molvis/v17/a228> © 2011 Molecular Vision
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.To the best of our knowledge, this is the first report on
molecular genetic analysis of PCG in the Korean population.
One fourth of Korean PCG probands were found to have at
least  one  CYP1B1  mutation  and  half  of  the  patients  with
CYP1B1 mutations had only one mutant allele. We observed
a  high  degree  of  allelic  heterogeneity  in  our  cohort  with
CYP1B1  mutations.  Only  two  patients  carried  possible
MYOC mutations. These results suggest that CYP1B1 should
be regarded as a potential primary cause of PCG in Korea.
However, due to the relatively low contribution of CYP1B1
to  Korean  PCG,  it  is  suggested  that  other  genetic  factors
remain to be identified and that further work is needed to
identify the causative genes.
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